Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
Yoo T, Heiling H, Santos K, Lipsyc-Sharf M, De Bruin E, Patel A, Kirkner G, Hughes M, Partridge A, Krop I, Howarth K, Winer E, Tolaney S, Tayob N, Lin N, Parsons H. Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study. Journal Of Clinical Oncology 2025, 43: 3055-3055. DOI: 10.1200/jco.2025.43.16_suppl.3055.Peer-Reviewed Original ResearchHR+/HER2- breast cancerNegative predictive valueAdjuvant settingBreast cancerFollow-upCtDNA testingDistant recurrenceClinical outcomesPlasma samplesHER2-negative breast cancerEarly-stage breast cancerRoutine surveillance imagingHormone receptor-positiveStage III diseaseYrs of follow-upMedian Follow-UpCirculating tumor DNALack of clinical recurrenceRisk of recurrenceFollow-up periodFollow-up visitMedian lead timeImpact clinical outcomesGuideline-concordant careCtDNA-negative
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply